Escoublac was established based on the discovery that osteocalcin, a protein found in bone and dentin, plays a role in energy metabolism and related disorders. The research findings, published in the August 2007 issue of the peer-reviewed scientific journal Cell, demonstrated that osteocalcin encouraged weight loss, increased the production of insulin-generating beta cells as well as insulin, and improved sensitivity to insulin. The company aims to transform this discovery into new therapies for metabolic disorders and related conditions, such as obesity and type 2 diabetes.

Contact Information

Escoublac's facilities are located at 241 Binney Street in Cambridge, MA.

Press Releases